Inflammatory Bowel Disease Linked to Prostate Cancer
|
By LabMedica International staff writers Posted on 18 Dec 2018 |

Image: Patients with inflammatory bowel disease who have an elevated PSA, may be at risk for prostate cancer (Photo courtesy of Harvard University).
About one million men have inflammatory bowel disease in the USA, a common chronic condition that includes Crohn's disease and ulcerative colitis. Epidemiologic studies have noted an association between chronic inflammation and prostate cancer.
Prostate cancer is cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and is initially confined to the prostate gland, where it may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.
A team of urologists and physicians working with the Northwestern University (Evanston, IL, USA) investigated 1,033 men with inflammatory bowel disease (IBD) and a control group of 9,306 men without the disease. They followed the two groups of men for 18 years and found those with IBD were much more likely to have prostate cancer and higher prostate specific antigen (PSA) levels. Follow-up time for all patients was the duration between a patient's first PSA test and last physician encounter. The median age of both case and control groups at first PSA measurement was 53 years, and 74% were white.
The scientists reported that the 5- and 10-year incidences of any prostate cancer (PCa) were 2.8% and 4.4% for cases and 0.25% and 0.65% for controls, respectively. The crude incidences of any PCa were 715 cases in patients with IBD and 167 cases among controls per 100 000 person-years. The incidences of clinically significant PCa were 462 cases in patients with IBD and 115 cases among controls per 100,000 person-years. A total of 27, 221 PSA measurements were assessed for men without IBD and 3,357 for men with IBD. There was a slight trend toward a higher number of PSA tests and higher PSA values among patients with IBD. While PSA estimates were similar in younger patients, age-specific PSA values were significantly higher in patients with IBD in older age, starting at approximately age 60.
The authors concluded that in a retrospective matched-cohort study, men with IBD who underwent PSA-based PCa screening had higher rates of any and clinically significant PCa when compared with age- and race-matched men without IBD. These findings warrant future prospective investigation to better understand the relationship between IBD and PCa.
Shilajit D. Kundu, MD, an associate professor of urology and senior author of the study, said, “These patients may need to be screened more carefully than a man without inflammatory bowel disease. If a man with inflammatory bowel disease has an elevated PSA, it may be an indicator of prostate cancer. Many doctors think when the PSA is elevated, it is just because they have an inflammatory condition. There is no data to guide how we should treat these men.” The study was published on December 4, 2018, in the journal European Urology.
Related Links:
Northwestern University
Prostate cancer is cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and is initially confined to the prostate gland, where it may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.
A team of urologists and physicians working with the Northwestern University (Evanston, IL, USA) investigated 1,033 men with inflammatory bowel disease (IBD) and a control group of 9,306 men without the disease. They followed the two groups of men for 18 years and found those with IBD were much more likely to have prostate cancer and higher prostate specific antigen (PSA) levels. Follow-up time for all patients was the duration between a patient's first PSA test and last physician encounter. The median age of both case and control groups at first PSA measurement was 53 years, and 74% were white.
The scientists reported that the 5- and 10-year incidences of any prostate cancer (PCa) were 2.8% and 4.4% for cases and 0.25% and 0.65% for controls, respectively. The crude incidences of any PCa were 715 cases in patients with IBD and 167 cases among controls per 100 000 person-years. The incidences of clinically significant PCa were 462 cases in patients with IBD and 115 cases among controls per 100,000 person-years. A total of 27, 221 PSA measurements were assessed for men without IBD and 3,357 for men with IBD. There was a slight trend toward a higher number of PSA tests and higher PSA values among patients with IBD. While PSA estimates were similar in younger patients, age-specific PSA values were significantly higher in patients with IBD in older age, starting at approximately age 60.
The authors concluded that in a retrospective matched-cohort study, men with IBD who underwent PSA-based PCa screening had higher rates of any and clinically significant PCa when compared with age- and race-matched men without IBD. These findings warrant future prospective investigation to better understand the relationship between IBD and PCa.
Shilajit D. Kundu, MD, an associate professor of urology and senior author of the study, said, “These patients may need to be screened more carefully than a man without inflammatory bowel disease. If a man with inflammatory bowel disease has an elevated PSA, it may be an indicator of prostate cancer. Many doctors think when the PSA is elevated, it is just because they have an inflammatory condition. There is no data to guide how we should treat these men.” The study was published on December 4, 2018, in the journal European Urology.
Related Links:
Northwestern University
Latest Pathology News
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
- AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
- Deep Learning–Based Method Improves Cancer Diagnosis
- ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
- New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







